- Home
- SERA vs ZNTL Comparison
SERA vs ZNTL Comparison
Compare SERA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- ZNTL
- Stock Information
- Founded
- SERA 2008
- ZNTL 2014
- Country
- SERA United States
- ZNTL United States
- Employees
- SERA N/A
- ZNTL N/A
- Industry
- SERA Precision Instruments
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SERA Health Care
- ZNTL Health Care
- Exchange
- SERA Nasdaq
- ZNTL Nasdaq
- Market Cap
- SERA 90.6M
- ZNTL 105.8M
- IPO Year
- SERA 2021
- ZNTL 2020
- Fundamental
- Price
- SERA $3.15
- ZNTL $1.48
- Analyst Decision
- SERA
- ZNTL Buy
- Analyst Count
- SERA 0
- ZNTL 7
- Target Price
- SERA N/A
- ZNTL $8.46
- AVG Volume (30 Days)
- SERA 109.9K
- ZNTL 830.4K
- Earning Date
- SERA 11-05-2025
- ZNTL 11-11-2025
- Dividend Yield
- SERA N/A
- ZNTL N/A
- EPS Growth
- SERA N/A
- ZNTL N/A
- EPS
- SERA N/A
- ZNTL N/A
- Revenue
- SERA $108,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- SERA $257.66
- ZNTL N/A
- Revenue Next Year
- SERA $435.22
- ZNTL N/A
- P/E Ratio
- SERA N/A
- ZNTL N/A
- Revenue Growth
- SERA 0.94
- ZNTL N/A
- 52 Week Low
- SERA $1.37
- ZNTL $1.01
- 52 Week High
- SERA $9.13
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- SERA 58.18
- ZNTL 42.63
- Support Level
- SERA $2.97
- ZNTL $1.60
- Resistance Level
- SERA $3.30
- ZNTL $2.02
- Average True Range (ATR)
- SERA 0.30
- ZNTL 0.12
- MACD
- SERA -0.00
- ZNTL -0.04
- Stochastic Oscillator
- SERA 57.46
- ZNTL 3.32
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.